Filing Flows › NovoCure (NVCR) › Q3 2026 › vs Q3 2025
NovoCure (NVCR) Q3 2026 vs Q3 2025 (year over year)
NovoCure's revenue rose $26.2M (+16%) from $167M in Q3 2025 to $193M in Q3 2026.
NovoCure, Q3 2026: revenue $193M (+16% year over year), operating margin -3.2%, net loss $10.4M, operating cash flow $22.7M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 8.1% | 8.9% | -0.8 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $193M | $167M | $26.2M | +16% |
| Net loss | $10.4M | $37.3M | −$26.8M | -72% |
| Costs & expenses | $204M | $210M | −$6.6M | -3% |
| Operating costs | $200M | $203M | −$3.7M | -2% |
| Interest & other, net | $1.7M | −$6.0M | $7.7M | — |
| Income tax | $2.6M | $7.2M | −$4.7M | -65% |
| Cost of revenue | $44.5M | $44.7M | −$200K | -0.4% |
| Research & development | $58.1M | $54.0M | $4.1M | +8% |
| Sales & marketing | $53.3M | $58.5M | −$5.2M | -9% |
| General & admin | $43.6M | $45.9M | −$2.3M | -5% |
| Operating cash sources | $33.1M | $57.8M | −$24.7M | -43% |
| Depreciation & amortization | $4.4M | $3.7M | $753K | +21% |
| Share-based compensation | $17.5M | $29.3M | −$11.8M | -40% |
| Working capital & other | $11.2M | $24.9M | −$13.7M | -55% |
| Net loss absorbed | $10.4M | $37.3M | −$26.8M | -72% |
| Operating cash flow | $22.7M | $20.6M | $2.1M | +10% |
| Free cash flow (OCF − capex) | $15.7M | $14.9M | $827K | +6% |
| Capital expenditures | $6.9M | $5.7M | $1.3M | +22% |
Questions
How much did NovoCure's revenue grow year over year in Q3 2026?
NovoCure's revenue rose $26.2M (+16%) from $167M in Q3 2025 to $193M in Q3 2026.